Citius Pharma Analyst Ratings
EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product Data
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
Citius Pharma Analyst Ratings
Citius Pharmaceuticals Price Target Maintained With a $6.00/Share by EF Hutton
Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
EF Hutton Initiates Coverage On Citius Pharma With Buy Rating, Announces Price Target of $6
Citius Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Citius Pharma Analyst Ratings